BARLAAM, BERNARD CHRISTOPHE,巴兰 伯纳德 克里斯多夫,巴蘭 伯納德 克里斯多夫,PIKE, KURT GORDON,派克 科特 高登,派克 科特 高登
申请号：
TW106109172
公开号：
TW201808939A
申请日:
2017.03.20
申请国别(地区):
TW
年份:
2018
代理人:
摘要：
This specification generally relates to compounds of Formula (I): And pharmaceutically acceptable salts thereof, where R1, R2 and R3 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof； pharmaceutical compositions comprising such compounds and salts thereof； kits comprising such compounds and salts thereof； methods of manufacture of such compounds and salts thereof； intermediates useful in the manufacture of such compounds and salts thereof； and to methods of treating ATM kinase mediated disease, including cancer, using compounds of Formula (I) and salts thereof alone or in combination with other therapies.本說明書總體上涉及具有化學式(I)之化合物：及其藥學上可接受的鹽，其中R1、R2和R3具有本文定義的含義中的任一者。本說明書還涉及此類化合物及其鹽用以治療或預防ATM激酶介導的疾病包括癌症之用途。本說明書進一步涉及具有化學式(I)之化合物及其藥學上可接受的鹽的結晶形式；包含此類化合物及其鹽的醫藥組成物；包含此類化合物及其鹽之套組；生產此類化合物及其鹽之方法；在生產此類化合物及其鹽中有用的中間體；並且涉及單獨地使用具有化學式(I)之化合物及其鹽或與其他療法組合治療ATM激酶介導的疾病包括癌症之方法。
